1. The application relates to an antibody or antibody fragment with calcium phosphate binding ability and / or phosphine copolymer, wherein the antibody or antibody fragment comprises a variable heavy chain domain and / or a variable light chain domain (VL), wherein the VH domino plate comprises a sequence 2. Amino acids, including one, two or preferably three complementary determining regions selected from the group, consisting of a series of carbon tetrachloride containing at least 25% of the amino acid sequence；fifty percent75% or 100% of our 17 sequence； one that contains at least 5% of our amino acid sequence,Page: 1seventeen percentPage: 1Page: 1thirty-five percentforty-seven percentfifty-two percentPage: 1sixty-four percentseventy percentseventy-six percenteighty-two percent94% or 100% of ID 18 sequence and CDR3 sequence, including at least 4% of amino acid sequence,Page: 1Page: 1Page: 1Page: 1twenty-seven percentPage: 1Page: 1forty percentforty-five percentfifty percentfifty-four percentPage: 1sixty-three percentsixty-eight percent72%.seventy-seven percenteighty-one percenteighty-six percentninety percent95% or 100% of the ID sequence numbers are 19, 20, 21 or 22； and / or (b) the VL domain includes an amino acid sequence, including an amino acid sequence, Two or preferably three complementary regions selected from this group consist of a fourth catalytic decomposition sequence containing at least 5% of the amino acid sequence,Page: 1seventeen percentPage: 1Page: 1thirty-five percentforty-seven percentfifty-two percentPage: 1sixty-four percentseventy percentseventy-six percenteighty-two percent94% or 100% of our 23 or 24 sequences； a cdr5 sequence with at least 14% of the amino acid sequence,Page: 1forty-two percentPage: 1Page: 185% or 100% of our 25 sequence； a 6 sequence with at least 11% of our amino acid sequence,Page: 1Page: 1forty-four percentPage: 1Page: 1seventy-seven percent88% or 100% of serial numbers and SEC 26.La presente solicitud se relaciona
